Articles from Endospan

Endospan Announces Positive One-Year Data from TRIOMPHE FDA Pivotal Study For the NEXUS® Aortic Arch Stent-Graft System
Endospan, a privately held company pioneering solutions for the endovascular repair of aortic arch disease, today announced the one-year results of their TRIOMPHE Investigational Device Exemption (IDE) Study evaluating the NEXUS® Aortic Arch Stent-Graft System presented during the Society of Thoracic Surgeons (STS) Annual Meeting in New Orleans.
By Endospan · Via Business Wire · February 3, 2026
Endospan Announces Positive 30-Day Data from TRIOMPHE FDA Clinical Study of NEXUS® Aortic Arch Stent-Graft
Endospan today announced the presentation of 30-day results of the statistical Dissection Primary Arm from the TRIOMPHE Investigational Device Exemption (IDE) clinical study evaluating the NEXUS® Aortic Arch Stent-Graft System. The data were presented during the late-breaking trial session at the American Association for Thoracic Surgery (AATS) Annual Meeting in Seattle.
By Endospan · Via Business Wire · May 5, 2025
Endospan Completes Enrollment of Primary Arm in NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Clinical Study
Endospan, a pioneer in endovascular solutions for the Aortic Arch, today announced the completion of enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study for the NEXUS® Aortic Arch Stent Graft. The study is evaluating the safety and efficacy of the device for the treatment of aortic arch disease.
By Endospan · Via Business Wire · October 21, 2024
Endospan Releases Early TRIOMPHE IDE Study Results at Society of Thoracic Surgeons
Endospan is a pioneer in off-the-shelf endovascular repair of aortic arch disease. As a notice of availability to educate potential referring physicians about the TRIOMPHE study, Endospan shared the 30-day results of the first 22 patients enrolled in the TRIOMPHE IDE study in a Late-Breaking presentation at the 60th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas this past weekend. TRIOMPHE is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and effectiveness of NEXUS® in treating thoracic aortic lesions involving the aortic arch. The study will enroll 110 patients at up to 31 sites.
By Endospan · Via Business Wire · January 30, 2024
Endospan Announces Initial Experience with the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System
Endospan, a pioneer in endovascular repair of aortic arch disease, announces the initial experience with its custom-made NEXUS DUO™ Aortic Arch Stent Graft System. Prof. Th. Bisdas, from the Athens Medical Centre, presented the multicentric European experience of the first ten patients treated with NEXUS DUO at the Leipzig Interventional Course (LINC) on June 8th, 2023.
By Endospan · Via Business Wire · June 19, 2023
Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System
Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces publication a head-of-print in the Annals of Surgery of the “NEXUS Arch Multicenter Study Evaluating the Initial Experience with a Novel Aortic Arch Stent Graft System” by Planer et al.
By Endospan · Via Business Wire · November 1, 2021